Author name: Leonardo Arias

La levadura, ese organismo microscópico que ha acompañado a la humanidad desde tiempos ancestrales, ha dejado de ser solo un aliado en la cocina para convertirse en protagonista de investigaciones científicas, procesos industriales e innovaciones médicas. Pero ¿de …

The mad rush for safe and effective obesity drugs has winners—including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—and losers. Here are five molecules that never made it to the market.

The final settlement wraps up 12 years of litigation over Blue Cross and Blue Shield plans’ alleged collusion to lower reimbursement to U.S. providers.

The data breach is one of the largest healthcare incidents reported to federal regulators this year.

After a busy summer of surgical robotics news, check out MedTech Dive’s roundup of coverage in the space.

The trade group wants the U.S. to eliminate tariffs on medical technologies, warning that “patients cannot be collateral damage in trade tensions.”

With results from highly anticipated trials of Eli Lilly’s orforglipron and Viking Therapeutics’ VK2735 “underwhelming” investors, William Blair’s Andy Hsieh predicts weight loss pills will play a bigger role in low- and middle-income countries than in the U.S.

While it’s impossible to make apples-to-apples comparisons of the many obesity candidates with so many differences across clinical trials, we at BioSpace are giving it our best shot.

There’s still much more to come from the White House on tariffs, but the European Union has now reached a trade agreement with the U.S.

Krystal Biotech’s decision follows the FDA’s rejection last month of Replimune’s RP1, which works similarly to Krystal Biotech’s KB707. The biotech said this has introduced “heightened uncertainty” regarding a potential accelerated pathway for the candidate.